Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapyAlessandra Fabi, Francesco Cognetti, Michelangelo Russillo et al.|BMC Cancer|2012Cited by 22
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world settingLaura Pizzuti, Nicola Tinari, Eriseld Krasniqi et al.|Therapeutic Advances in Medical Oncology|2021Cited by 10
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational studyFrancesca Sofia Di Lisa, Enzo Veltri, Eriseld Krasniqi et al.|Frontiers in Oncology|2023Cited by 9
Abstract P1-11-13: DE-REAL: ITALIAN MULTICENTER EXPERIENCE OF TRASTUZUMAB DERUXTECAN IN A REAL WORLD SETTINGAndrea Botticelli, Alessandra Fabi, Simone Scagnoli et al.|Cancer Research|2023Cited by 1
Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients.Alessandra Fabi, F. Cognetti, G. Ferretti et al.|Journal of Clinical Oncology|2011Cited by 0